Iovance Biotherapeutics Inc (STU:2LB)
€ 10.415 0.26 (2.56%) Market Cap: 3.20 Bil Enterprise Value: 2.89 Bil PE Ratio: 0 PB Ratio: 4.43 GF Score: 39/100

Q1 2021 Iovance Biotherapeutics Inc Earnings Call Transcript

May 06, 2021 / 08:30PM GMT
Release Date Price: €23.06 (-5.34%)
Operator

Hello, and welcome to the Iovance Biotherapeutics First Quarter 2021 Financial Results Conference. My name is Michelle, and I will be the operator on today's call. (Operator Instructions)

I will now turn the call over to Ms. Sara Pellegrino. Ma'am, you may begin.

Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations

Thank you, operator. Good afternoon, and thank you for joining us. Speaking on today's call, we have Maria Fardis, our President and Chief Executive Officer; Friedrich Finckenstein, our Chief Medical Officer; and Jean-Marc Bellemin, our Chief Financial Officer. We are also joined by Jim Ziegler, Senior Vice President, Commercial. This afternoon, we issued a press release that can be found on our website at iovance.com, which includes the financial results for the 3 months ended on March 31, 2021, as well as corporate update.

Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking statements regarding Iovance's goals, business focus,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot